Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

April 1, 2014

Pharmacoeconomics: Five Simple and Effective Ways to Optimize Budget Impact Analyses and Obtain Drug Reimbursement

Speaker for this Event:

  • Marie Maxime Hubert, M.Sc., Manager, Health Economics and Outcomes Research, JSS Medical Research Inc.   
  • This pharmacoeconomics webinar focuses on one of the key elements of the reimbursement dossier: the budget impact analysis. Five considerations are discussed to optimize the budget impact analysis’ methodology. Applying these suggestions results in a pharmacoeconomic analysis that better reflects real-life outcomes and therefore provides more realistic sales forecasts.

    Why perform budget impact analyses as a supplement to pharmacoeconomic analyses? Obtaining drug reimbursement has never been as difficult as it presently is. In Canada, manufacturers requesting reimbursement by public drug plans are required to produce a voluminous submission including, in addition to the clinical evidence: the burden of illness, the costs associated with the disease, a systematic review of literature, a thorough analysis of the cost-effectiveness of the product (preferably over the patient’s lifetime) and the budget impact analysis.

    It is now recognized that the drug coverage on public drug plans directly affects the prescribing patterns of physicians, regardless of coverage on more generous private drug plans.

    Moreover, it is of the utmost importance to file the reimbursement request as soon as the marketing authorization from Health Canada is granted, and to do so, it is necessary to have the submission ready beforehand. A delay in reimbursement is synonymous to a delay in reaching full market access potential, which would not deprive a company of their initial sales, but rather deprive of the peak sales achieved just before the end of patent exclusivity.

    The presentation focuses on one of the key mandatory elements of the reimbursement dossier: the budget impact analysis (BIA). In a nutshell, the BIA can be described as a precise estimate of anticipated incremental expenditures following reimbursement of the drug. It is a forecast of the drug sales for the submitted indication, with and without the reimbursement of the new drug. The impact is obtained by subtracting the expenditures predicted in the reimbursement scenario from the expenditures predicted in the status quo scenario. In Canada, this analysis is performed for each provincial and federal drug plan, capturing drug costs over a period of three years. Other costs that are often included are pharmacy dispensing fees and administration costs. Other healthcare costs, such as hospitalization and physician visits, are not included in the BIA but in the pharmacoeconomic analysis, which complements the BIA by demonstrating the drug’s value for money.


    Senior level executives and analysts from pharmaceutical and biotechnology companies involved in the following areas:

    • Market Access
    • Patient Access
    • Reimbursement
    • Health Economics
    • Health Economics and Outcomes Research (HEOR)
    • Private payer strategy
    • Governmental affairs
    • Market research, forecasting
    • Marketing

    This session will be beneficial to those with prior understanding of drug reimbursement processes and budget impact analyses.


    Marie Maxime Hubert, M.Sc., Manager, Health Economics and Outcomes Research, JSS Medical Research Inc.

    Marie Maxime is a project leader with a unique combination of scientific and economic expertise. She is an excellent communicator who aspires to deliver healthcare solutions. She holds a bachelor in biomedical sciences, a graduate diploma in drug development and a master’s degree in pharmaceutical sciences with a double specialization in pharmacoepidemiology and pharmacoeconomics. She gained a practical understanding of economics, data analysis and drug policies as economic consultant at IMS Health. She has extensive experience building reimbursement dossiers from roles in multinational pharmaceutical companies (Sanofi-Aventis and AbbVie, formerly Abbott). She also reviewed reimbursement submissions as part of her duties on the common drug review at the Canadian agency for drugs and technologies in health. She is currently expanding the health economics and outcomes research franchise at JSS Medical Research, a contractual research organization with over 25 years of experience in clinical research, biostatistics and epidemiology.


    Founded in 1985, JSS Medical Research Inc. is a contract research organization (CRO) that offers patient access services in addition to clinical research, such as: economic analyses for reimbursement, the collection of patient-reported outcomes alongside clinical trials, the complete management of post-marketing observational studies, registries and administrative databases, meta-analyses, drug utilization reviews and medical writing. Being a science-based CRO, JSS Medical Research understands the science behind pharmaceutical market dynamics and has the expertise required to guide companies in the drug reimbursement process. JSS Medical Research earned its credibility from delivering high quality, scientifically rigorous and sound clinical research services.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Share this:

    Copyright © 2016-2017 Honeycomb Worldwide Inc.